Pseudogout Prophylaxis
For patients with recurrent pseudogout attacks, initiate colchicine 0.6 mg twice daily (or 0.5 mg twice daily outside the US) as first-line prophylaxis, with low-dose NSAIDs (e.g., naproxen 250 mg twice daily with PPI) as second-line if colchicine is contraindicated or not tolerated.
Evidence Base and Rationale
While the available guidelines 1 and newer recommendations 2, 3 focus primarily on gout prophylaxis (not pseudogout), the clinical approach to pseudogout prophylaxis follows similar principles based on the limited but supportive research evidence available.
Key Research Evidence for Pseudogout
The strongest direct evidence comes from a small but well-designed study 4 that demonstrated colchicine 0.6 mg twice daily reduced pseudogout attacks from 3.2 episodes per patient per year to 1 episode per patient per year (p < 0.001), with 90% of patients benefiting from prophylaxis. This represents a 69% reduction in attack frequency.
Additional case series 5 support colchicine 1 mg/day for prophylaxis in specific high-risk scenarios (post-parathyroidectomy pseudogout), and recent case reports 6 describe successful management with both colchicine and corticosteroids in tacrolimus-induced pseudogout.
Prophylaxis Algorithm
First-Line: Colchicine
- Dose: 0.6 mg twice daily (or 0.5 mg twice daily outside US)
- Alternative: 0.6-1 mg once daily if twice-daily dosing not tolerated
- Duration: Continue as long as patient experiences recurrent attacks (typically long-term)
Dose Adjustments Required:
- Renal impairment: Reduce dose (specific adjustment based on CrCl)
- Drug interactions: Avoid with strong P-glycoprotein or CYP3A4 inhibitors (cyclosporin, clarithromycin)
- Concurrent statin use: Monitor for neurotoxicity and muscle toxicity
Second-Line: Low-Dose NSAIDs
- Dose: Naproxen 250 mg twice daily (or equivalent NSAID)
- Always add: Proton pump inhibitor for GI protection
- Use when: Colchicine contraindicated, not tolerated, or ineffective
Third-Line: Low-Dose Corticosteroids
- Dose: Prednisone/prednisolone <10 mg/day
- Use when: Both colchicine and NSAIDs are contraindicated, not tolerated, or ineffective
- Caution: Higher doses (>10 mg/day) lack consensus for prophylaxis
Critical Contraindications and Pitfalls
Absolute contraindications to colchicine:
- Concurrent use of strong P-glycoprotein inhibitors (cyclosporin, clarithromycin, ritonavir)
- Severe renal impairment with concurrent CYP3A4 inhibitors
- Severe hepatic impairment with concurrent drug interactions
Common pitfalls:
- Using full therapeutic doses instead of prophylactic doses
- Failing to adjust for renal function
- Missing drug-drug interactions, particularly with statins
- Discontinuing prophylaxis prematurely when attacks decrease
Special Populations
Post-surgical patients (especially post-parathyroidectomy): Consider initiating colchicine 1 mg/day prophylactically if chondrocalcinosis identified on preoperative imaging 5.
Patients on calcineurin inhibitors (tacrolimus, cyclosporin): Higher risk of pseudogout due to hypomagnesemia 6. Monitor magnesium levels and consider prophylaxis if recurrent attacks occur. Note the drug interaction concern with cyclosporin and colchicine.
Duration of Therapy
Unlike gout prophylaxis (which has defined 3-6 month duration when initiating urate-lowering therapy 3), pseudogout prophylaxis typically requires indefinite continuation as there is no disease-modifying therapy equivalent to urate-lowering therapy. Reassess periodically (every 6-12 months) to determine if prophylaxis remains necessary based on attack frequency.
Monitoring
- Attack frequency: Document number of attacks before and during prophylaxis
- Adverse effects: GI symptoms (diarrhea, nausea), muscle weakness, neuropathy
- Drug interactions: Review medication list at each visit
- Renal function: Monitor creatinine, adjust colchicine dose accordingly
- Magnesium levels: Especially in patients on calcineurin inhibitors